Akston Biosciences
Akston Biosciences is dedicated to accelerating the next revolution in pet health by designing, developing, and manufacturing species-specific protein therapeutics. They leverage their proprietary Ambifect® Fc-fusion platform to create innovative biologics and vaccines for veterinary use, with a focus on cost-effective, stable, and targeted treatments. The company operates a vertically integrated, GMP-compliant manufacturing facility in Beverly, Massachusetts, and collaborates with strategic partners to bring advanced therapies to market. Their mission is to provide pets with biotech therapies that improve their health and strengthen bonds with their families.
Industries
Nr. of Employees
medium (51-250)
Akston Biosciences
100 Cummings Center, Suite 455B, Beverly, MA 01915
Patents
Products
Ambient‑stable Fc-fusion subunit vaccine (clinical-stage candidate)
A subunit vaccine construct consisting of a target antigen fused to an Fc domain formulated for stability at elevated temperatures to enable low-cost, high-volume distribution without cold-chain dependence.
Antigen-specific immunotherapy (autoimmune indication candidate)
Fc-fusion biologic designed to present disease-specific epitopes to the immune system to induce selective deletion or tolerance of autoreactive B or T cells.
Ultra‑long‑acting insulin biologics for companion animals
Modified insulin therapeutics engineered for once‑weekly dosing in dogs and cats through sequence modifications and Fc domain selection to extend half-life and maintain glucose-lowering control.
Therapeutic vaccine candidates for animal indications (chronic pain, atopic dermatitis, cancer targets)
Platform-derived therapeutic vaccine constructs targeting proteins implicated in chronic pain and atopic dermatitis, and immunotherapies for oncology indications in companion animals.
Ambient‑stable Fc-fusion subunit vaccine (clinical-stage candidate)
A subunit vaccine construct consisting of a target antigen fused to an Fc domain formulated for stability at elevated temperatures to enable low-cost, high-volume distribution without cold-chain dependence.
Antigen-specific immunotherapy (autoimmune indication candidate)
Fc-fusion biologic designed to present disease-specific epitopes to the immune system to induce selective deletion or tolerance of autoreactive B or T cells.
Ultra‑long‑acting insulin biologics for companion animals
Modified insulin therapeutics engineered for once‑weekly dosing in dogs and cats through sequence modifications and Fc domain selection to extend half-life and maintain glucose-lowering control.
Therapeutic vaccine candidates for animal indications (chronic pain, atopic dermatitis, cancer targets)
Platform-derived therapeutic vaccine constructs targeting proteins implicated in chronic pain and atopic dermatitis, and immunotherapies for oncology indications in companion animals.
Services
Manufacture of GMP drug substance at multi-kilogram scale with integrated process development and GMP quality control support for veterinary biologics.
Product-scale process development services including optimization for single-use systems and scale-up planning to support clinical and commercial supply.
GMP QC laboratory testing and release assays including immunogenicity, binding, and neutralization assays to support clinical development and product release.
Execution and coordination of toxicology, safety pharmacology, in vivo assay validation, and large-animal studies required for IND submissions.
Structuring and executing licensing, development, supply, and commercialization agreements for veterinary biologics with global partners.
Manufacture of GMP drug substance at multi-kilogram scale with integrated process development and GMP quality control support for veterinary biologics.
Product-scale process development services including optimization for single-use systems and scale-up planning to support clinical and commercial supply.
GMP QC laboratory testing and release assays including immunogenicity, binding, and neutralization assays to support clinical development and product release.
Execution and coordination of toxicology, safety pharmacology, in vivo assay validation, and large-animal studies required for IND submissions.
Structuring and executing licensing, development, supply, and commercialization agreements for veterinary biologics with global partners.
Expertise Areas
- Protein therapeutics (Fc-fusion) development
- Companion animal biologics and veterinary therapeutics
- Vaccine design and development (subunit/Fc-fusion)
- Ultra‑long‑acting insulin and endocrine biologics
Key Technologies
- Fc-fusion protein therapeutics
- Subunit vaccine design (antigen-Fc constructs)
- Species-specific Fc engineering
- FcRn-mediated half-life extension
News & Updates
Akston received the 2024 Best Start-Up Award at the Animal Health Summit in London, recognizing its innovative biotech solutions for pets.
Akston partnered with LakePharma to manufacture and develop AKS-452, a stable COVID-19 vaccine candidate, which is entering clinical trials.
Akston raised $3.9 million in Series D funding to accelerate insulin and cancer therapy development.
The company signed a lease and started construction of a new biologics manufacturing facility in Beverly, MA.
The NIH awarded Akston $978,643 for studies on AKS-107 for Type 1 Diabetes prevention.
Recognition for Akston’s innovative approach to pet biotech and its strategic partnerships.
Akston received the 2024 Best Start-Up Award at the Animal Health Summit in London, recognizing its innovative biotech solutions for pets.
Akston partnered with LakePharma to manufacture and develop AKS-452, a stable COVID-19 vaccine candidate, which is entering clinical trials.
Akston raised $3.9 million in Series D funding to accelerate insulin and cancer therapy development.
The company signed a lease and started construction of a new biologics manufacturing facility in Beverly, MA.
The NIH awarded Akston $978,643 for studies on AKS-107 for Type 1 Diabetes prevention.
Recognition for Akston’s innovative approach to pet biotech and its strategic partnerships.